Provider review
Noom Med Review: Plans and Results
Noom Med combines prescribing with app-based behavior support, but its plans differ in medicine and billing. The current results are self-reported program data; greater app engagement is associated with better outcomes, not proof that the app caused them.
Some links on this site are affiliate links, and we may earn a commission. How we’re paid
Visit Noom MedOf Noom Med’s 1 dated product claim documented below, 1 is consistent with the cited evidence. Comparable upfront pricing is not established here. Evidence for a medicine does not establish the quality of this provider’s care.
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
FDA-approved
Phase 3 trials
Not confirmed
None found
Provenance
Products reviewed at Noom Med
These evidence cards classify the treatments evaluated in this review. Confirm the exact medicine and formulation proposed for your prescription with the care team.
The finished product holds an FDA approval and carries an NDC. Approval covers the specific product, dose form and indication on the label — not the molecule in general.
- Wegovy injection (approved option)
Evidence
Has the molecule been tested for what it is sold for?
Each row summarizes human evidence for the molecule and the use being advertised. Results apply to the product, dose, population and outcome studied; they do not establish that this provider’s preparation or program produces the same results. Compounded drugs are not FDA-approved. Evidence for one use should not be assumed to support another.
1
Products with human evidence
For the advertised use, out of 1 product reviewed here. The evidence concerns the molecule, not Noom Med's service.
1
Registry records cited
Distinct ClinicalTrials.gov records cited across the reviewed products. Registration alone does not establish that a treatment works.
The comparison
What they claim, against what the trials show
Each claim below is quoted word for word from Noom Med’s own page. Tap a row to see the quote, the trials behind it, and why it got that verdict.
Wegovy injection (approved option)Semaglutide · FDA-approvedClaim matches the trials
“brand-name medications like Wegovy® and Zepbound®”
Read on the Noom Med site, October 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. Manufacturer injection trial, not a randomized test of this care platform.
The named approved medicine has clinical trial evidence. This does not validate every other formulation or establish that the service improves outcomes compared with another prescriber.2
Dispensing chain
Who actually fills your prescription
Read the full account
The reviewed pages do not identify the pharmacy assigned to an individual prescription. Obtain its name and contact details before relying on a medication offer.
Read on the Noom Med site, October 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Not established in this source review
Certificate of analysis readable
A readable lot report was not verified here
Read the full testing account
Noom says pharmacy partners use third-party batch testing. This review did not inspect a batch report or a dispensed package; that statement is not independent verification of compounded product quality.
Read on the Noom Med site, October 2026.
Licensing
Licensed to dispense, and where
Coverage
Not available in all 50 states; confirm the selected plan and treatment.
Read the full licensing claim
This review does not independently verify every clinician license. Confirm the treating clinician and eligibility for the specific medicine in your state.
Read on the Noom Med site, October 2026.
Regulatory
The FDA warning letter
No FDA warning letter found
Assessment
What holds up, and what does not
- The pricing page distinguishes three bundled treatment offers.
- Outcome footnotes disclose self-reporting and selected participant groups.
- The engagement claim explicitly acknowledges that association is not causation.
- Continuing payments are quarterly despite monthly price labels.
- Consumer and clinician pages show different compounded semaglutide offers.
- The reviewed pages do not identify an individual prescription’s pharmacy.
Verdict
The bottom line
The pricing page distinguishes three bundled treatment offers. Continuing payments are quarterly despite monthly price labels.
Opens Noom Med's website. A link is not a recommendation to take anything.
Start with the exact Noom plan
Noom Med is not one medication offer. Its current pricing page lists Microdose GLP-1Rx, GLP-1Rx and GLP-1Rx Plus, each with a different introductory payment and continuing price. The page describes these offers as including clinical care, medication and the digital program. A separate clinician-facing page also describes access to branded medicines, including Wegovy and Zepbound, and cash-pay compounded options. 1 3
That distinction matters because an all-inclusive compounded offer should not be compared with a branded prescription whose drug charge may be separate. The pricing page itself warns that medication costs may not be included depending on the selected plan. Ask for the actual medicine, formulation and complete billing arrangement rather than relying on the Noom Med name alone. 1
The evidence card here covers the named approved Wegovy option. It does not imply that Noom's microdose or compounded programs are FDA-approved, nor that a manufacturer's trial tested Noom's care model. The label's evidence belongs to the specified finished medicine and population. 2
Full analysis — 5 more sectionsThe first four weeks are not the continuing bill · “Up to” is not the average result · More app use does not prove an app effect · What “microdose” leaves unanswered · The guarantee is a support benefit, not a refund promise
The first four weeks are not the continuing bill
The reviewed pricing page shows $79 to start Microdose GLP-1Rx, followed by $179 per month billed quarterly. GLP-1Rx starts at $129, then $249 per month billed quarterly. GLP-1Rx Plus starts at $149, then $299 per month billed quarterly. Each introductory amount refers to the first four-week supply. 1
Quarterly billing means the monthly number is not necessarily the amount charged at the next payment. Multiplying the displayed continuing monthly rates by three gives $537, $747 and $897 respectively. These are calculations from the advertised rates, not independently observed checkout totals or a statement that every person's offer will be identical.
There is also a discrepancy to resolve: Noom's clinician-facing page describes a compounded semaglutide offer at $149 initially and $279 per month for subsequent three-month supplies. Those figures differ from the current consumer pricing page. They may describe different offers, but the reviewed text does not reconcile them. Obtain the terms for the exact plan being offered to you. 3
“Up to” is not the average result
The consumer pricing page advertises up to 11 pounds in 60 days for the microdose program. Its footnote describes self-reported data from 7,377 users and an average of 7.6 pounds among those following the titration protocol. For GLP-1Rx it advertises up to 21 pounds in 90 days, alongside a 16.5-pound average in a 22,167-user dataset. 1
The Plus offer advertises up to 25 pounds in 90 days, with a footnoted average of 15.5 pounds among protocol followers in a much smaller dataset of 141 users. The different sample sizes and stated averages are important context. These are not three randomized groups that can establish which program works best. 1
Self-reporting, continued participation and adherence can affect which results are available. The footnotes help readers see those limits; the headline alone is less informative. Ask what happens to the reported outcome when people who discontinue or stop recording weight are included. Without that context, an impressive average can be mistaken for an expectation for every new member.
More app use does not prove an app effect
The page currently says Noom habits are associated with 37% more weight loss. Its footnote describes a January 2026 analysis of 14,203 GLP-1Rx members who actively logged weight over 40 weeks. Engagement groups were defined by app-opening frequency, and the disclosure explicitly says the association does not imply causation. 1
That is an appropriate qualification. People who use an app more often may differ in motivation, treatment persistence or other behaviors. A comparison of those groups cannot isolate what would have happened to the same person without the app. The finding may help describe engagement, but it does not establish a 37% guaranteed benefit from buying the subscription.
Noom's lessons, coaching and tracking may still be valuable to someone who wants that kind of support. Their usefulness is a separate, practical question: will you use them, and do they address the difficulties you expect during treatment? Choosing an app because it fits your routine is more defensible than assuming a promotional percentage measures its causal effect.
What “microdose” leaves unanswered
The microdose offer describes a low-dose approach designed to reduce observable side effects. The reviewed pricing page does not establish that this particular regimen has the same efficacy as an approved product's studied schedule, or quantify a randomized reduction in adverse events. Its program observations should not be substituted for that comparison. 1
Ask the prescriber what medicine is proposed, why the formulation and schedule fit your needs, and how response and side effects will be assessed. This review does not provide dosing instructions. A marketing term should not become a reason to combine products or change a prescription independently.
Noom says its pharmacy partners use third-party batch testing, but the reviewed clinician page does not identify the pharmacy assigned to an individual prescription or supply a patient-specific report. A testing statement is useful to ask about; it is not our independent verification of a dispensed preparation. 3
The guarantee is a support benefit, not a refund promise
The clinician page describes a taper-off guarantee as a free 12-month Noom Healthy Weight subscription for qualifying customers who do not maintain weight loss after medication withdrawal. That is different from returning medication fees or guaranteeing permanent weight maintenance. Ask for the eligibility conditions before treating the offer as protection against the financial cost of treatment. 3
Noom also says its programs are not available in all 50 states. Confirm eligibility for your selected plan and learn who will manage follow-up, particularly if you already have diabetes, eye disease or other ongoing care. Our diabetic-retinopathy review illustrates why coordination can matter beyond weight tracking.
Noom is most compelling when the reader wants its behavioral support and understands the specific medication arrangement. The next step is a clear plan-level quote and care discussion, not choosing whichever headline has the largest weight-loss number.
Questions
Frequently asked questions
Is the advertised monthly price billed monthly?
The three reviewed bundled offers say continuing supplies are billed quarterly. Confirm the amount and date of the next payment for your plan.
Does the 37% figure prove Noom causes more weight loss?
No. The cited analysis compares engagement groups, and Noom explicitly says the association does not imply causation.
Is the taper-off guarantee a medication refund?
The clinician page describes a free 12-month behavioral-program subscription for qualifying customers. It does not describe repayment of medication charges.
Compare
Others selling what Noom Med sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Ranked
The lists Noom Med is on
Method
How we checked this
Non-product facts last checked October 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off Noom Med's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 3 sources
- Noom (2026). Medication programs and pricing. Noom; accessed October 14, 2026. the Noom Med site
- FDA (2025). Wegovy prescribing information, revised August 2025. FDA; accessed October 14, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s026lbl.pdf
- Noom (2026). Information for healthcare providers. Noom; accessed October 14, 2026. the Noom Med site
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.